Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active.
Galvus (vildagliptin; Novartis) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
In 2015, the global point-of-care (POC) clinical diagnostic products market was valued at $14.7bn, comprising 28% of the total in-vitro diagnostics (IVD) market. The market is projected to grow at a somewhat slower rate than the overall IVD market, due mainly to a decline in the overall blood glucose self-testing segment, which comprises more than half of the POC diagnostics market.
Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.
Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.
Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.
The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.
Gilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5).
In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.
By any standards, last year was a turbulent one for the pharmaceutical sector. The patent cliff claimed some of the industry’s most profitable properties and with the market share of these drugs losing ground to generics, put even more pressure on the top- and bottom-line performance of key players such as Eli Lilly and AstraZeneca, to name just two of the worst hit.
Such pressure – and the drive to cut fixed costs that goes with it – has been a boon for clinical CROs, which have become increasingly indispensable to the business of drug discovery, as clinical development is outsourced and specialist units, such as clinical laboratories, are offloaded to CROs in long-term guaranteed strategic partnerships.
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.
Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
Coumadin is an orally available vitamin K antagonist (VKA) indicated for the prophylaxis and
treatment of deep vein thrombosis and pulmonary embolism.
Novartis first launched Exelon as a twice-daily oral formulation in Europe in 1998 and in the US in 2000 for the treatment of mild to moderate Alzheimer’s disease.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!